Milestone Pharma Q3 2026 Preview: CARDAMYST Rollout and AFib Trial Progress

MONTREAL and CHARLOTTE, N.C. – November 03, 2026 – The decentralization of healthcare has long been a theoretical ideal, but for patients suffering from acute cardiovascular episodes, it is rapidly becoming a tangible reality. Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company pioneering self-administered cardiovascular medicines, announced today that it will report its third-quarter 2026 financial results before the market opens on Friday, November 13, 2026. The release will be followed by a corporate business update and an investor webcast at 8:30 a.m. ET.

As the company prepares to open its books to Wall Street, industry observers are looking far beyond the top-line revenue. Milestone represents a critical test case in the broader medical technology frontier: the transition of acute, episodic care from the emergency room to the living room. With its lead commercial asset, CARDAMYST (etripamil) nasal spray, now navigating its first year on the retail market, the upcoming earnings call will provide a vital pulse check on the drug's commercial uptake, the company's cash runway, and the clinical progress of its ambitious pipeline expansion into atrial fibrillation.

Shifting PSVT Care from the Emergency Room to the Living Room

For decades, the standard of care for paroxysmal supraventricular tachycardia (PSVT)—a condition characterized by sudden, terrifying spikes in heart rate—has been inherently reactive and hospital-centric. Patients experiencing an episode typically face a frantic trip to the emergency department to receive intravenous antiarrhythmics like adenosine, diltiazem, or verapamil.

CARDAMYST, which secured FDA approval in December 2025 and hit U.S. retail pharmacies in early 2026, fundamentally alters this dynamic. As the first FDA-approved self-administered medicine for the conversion of acute symptomatic PSVT to normal sinus rhythm, it offers patients a rapid-response, portable therapy. Clinical data from the Phase 3 RAPID trial underscored this efficacy, demonstrating that 64% of patients using the nasal spray converted to a normal heart rhythm within 30 minutes, compared to just 31% on placebo. Furthermore, the median time to conversion was drastically reduced to 17 minutes, down from 54 minutes for the placebo group.

However, clinical triumph does not automatically translate to immediate commercial success. Milestone's second-quarter 2026 financials revealed the friction inherent in launching a novel therapeutic paradigm. The company reported Q2 revenue of $559,000, missing consensus estimates of $817,000, alongside an earnings per share (EPS) loss of $0.21.

Heading into the Q3 print, analysts are forecasting a consensus EPS of -$0.22. A critical metric for investors will be the expansion of reimbursement coverage, particularly within Medicaid. Medicaid populations account for roughly 10% of total PSVT patients. With more than half of total Medicaid lives now reportedly covered, securing comprehensive access in major markets like California and Texas remains a pivotal operational hurdle. The upcoming earnings call will likely shed light on whether prescription volumes are beginning to align with the drug's undeniable clinical utility.

The Next Frontier: Expanding Etripamil into Atrial Fibrillation

While PSVT serves as Milestone's commercial beachhead, the company's long-term valuation is heavily tethered to its clinical pipeline—specifically, the application of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR). AFib represents a significantly larger addressable market, and successfully migrating the self-administration model to this patient population could exponentially increase the company's footprint.

Milestone is currently advancing the Phase 3 ReVeRA-301 trial, a multinational, randomized, double-blind, placebo-controlled study evaluating etripamil nasal spray in approximately 150 patients with AFib-RVR. Mimicking the PSVT protocol, patients self-administer a 70 mg dose in a medically unsupervised setting. The primary endpoint is a measurable reduction in ventricular rate within 30 minutes, with secondary measures focusing on patient-reported symptom relief.

Recent clinical momentum suggests cautious optimism. Milestone recently enrolled its first European patient in the ReVeRA-301 trial, signaling an acceleration in global clinical operations. Furthermore, the company is slated to present compelling new data at the American Heart Association (AHA) Scientific Sessions 2026. A subgroup analysis of the Phase 3 RAPID trial showed that CARDAMYST successfully converted approximately two-thirds of patients with recurrent symptomatic PSVT—even after prior catheter ablation—to a normal heart rhythm within 30 minutes.

"Proving efficacy in post-ablation patients is a significant clinical milestone," noted one cardiovascular researcher observing the trial data. "It validates the nasal spray not just as a first-line alternative, but as a robust rescue therapy for complex arrhythmias." The company intends to leverage these findings as it pursues a supplemental new drug application (sNDA) for the AFib-RVR indication.

Balance Sheet Health Check: Cash Runway and Commercial Burn

The transition from a clinical-stage biotech to a commercial-stage pharmaceutical entity is notoriously capital-intensive, and Milestone's balance sheet reflects these growing pains. Currently trading as a micro-cap with a market capitalization hovering around $90.88 million, the company faces the dual financial burdens of funding a national commercial rollout for CARDAMYST while simultaneously sponsoring global Phase 3 trials for ReVeRA-301.

Over the trailing four quarters, Milestone has recorded a net income of -$63.06 million, generating an EPS of -$0.69. This cash burn is standard for emerging biopharma companies, but it places intense scrutiny on the company's liquidity and financing strategy. Adding to the friction, Milestone faced a Nasdaq listing compliance challenge in late October 2026, a procedural hurdle that often triggers anxiety among retail investors.

Despite these headwinds, institutional backing remains remarkably resilient. In the third quarter of 2026, Pavaki Capital Management LLC increased its ownership stake by nearly 3%, holding over 9.3 million shares valued at approximately $8 million as of September 30.

This institutional confidence is mirrored by Wall Street analysts, who maintain a "Moderate Buy" consensus rating. There is a stark disconnect between the company's current trading price of approximately $0.73 and the consensus price target of $6.40. This gap suggests that analysts believe the market is heavily discounting the long-term potential of the etripamil franchise, pricing in near-term commercial execution risks and potential dilution rather than the peak sales potential of a dual-indication cardiovascular asset.

Navigating the Competitive Landscape of Acute Arrhythmia

To understand Milestone's potential impact, one must look at the broader competitive dynamics of cardiovascular care. The industry is undergoing a profound structural shift. Healthcare systems, burdened by rising costs and emergency room overcrowding, are desperate for technologies that triage patients away from acute care settings.

CARDAMYST's primary competition is not necessarily another novel drug, but the entrenched behavioral loop of hospital admission. Intravenous adenosine, while highly effective, requires cardiac monitoring, a crash cart on standby, and the terrifying sensation of a brief cardiac pause for the patient. By replacing this traumatic, resource-heavy intervention with a simple, self-administered nasal spray, Milestone is not just selling a calcium channel blocker; it is selling patient autonomy and systemic cost avoidance.

"The ability to bypass the emergency department is not just a convenience; it is a fundamental restructuring of healthcare economics," explained a healthcare policy analyst familiar with the cardiovascular space. "If a patient can safely convert their own arrhythmia in their living room, the savings to the broader healthcare system are immense."

As Milestone Pharmaceuticals prepares to open its third-quarter earnings call on November 13, the stakes are clearly defined. The numbers will reveal the immediate trajectory of the CARDAMYST launch, but the underlying narrative will dictate the future of decentralized cardiovascular care. Investors and medical professionals alike will be listening closely to determine if this innovative approach to acute arrhythmia management can successfully cross the chasm from clinical breakthrough to commercial standard of care.